A citation-based method for searching scientific literature

Antoni Ribas, Jedd D Wolchok. Science 2018
Times Cited: 1833







List of co-cited articles
744 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Immune-Related Adverse Events Associated with Immune Checkpoint Blockade.
Michael A Postow, Robert Sidlow, Matthew D Hellmann. N Engl J Med 2018
15


Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Hossein Borghaei, Luis Paz-Ares, Leora Horn, David R Spigel, Martin Steins, Neal E Ready, Laura Q Chow, Everett E Vokes, Enriqueta Felip, Esther Holgado,[...]. N Engl J Med 2015
12

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
James Larkin, Vanna Chiarion-Sileni, Rene Gonzalez, Jean Jacques Grob, C Lance Cowey, Christopher D Lao, Dirk Schadendorf, Reinhard Dummer, Michael Smylie, Piotr Rutkowski,[...]. N Engl J Med 2015
12

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
12

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
Martin Reck, Delvys Rodríguez-Abreu, Andrew G Robinson, Rina Hui, Tibor Csőszi, Andrea Fülöp, Maya Gottfried, Nir Peled, Ali Tafreshi, Sinead Cuffe,[...]. N Engl J Med 2016
12

Improved survival with ipilimumab in patients with metastatic melanoma.
F Stephen Hodi, Steven J O'Day, David F McDermott, Robert W Weber, Jeffrey A Sosman, John B Haanen, Rene Gonzalez, Caroline Robert, Dirk Schadendorf, Jessica C Hassel,[...]. N Engl J Med 2010
10

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.
Robert J Motzer, Bernard Escudier, David F McDermott, Saby George, Hans J Hammers, Sandhya Srinivas, Scott S Tykodi, Jeffrey A Sosman, Giuseppe Procopio, Elizabeth R Plimack,[...]. N Engl J Med 2015
9

Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.
Luis Paz-Ares, Alexander Luft, David Vicente, Ali Tafreshi, Mahmut Gümüş, Julien Mazières, Barbara Hermes, Filiz Çay Şenler, Tibor Csőszi, Andrea Fülöp,[...]. N Engl J Med 2018
9

Hallmarks of cancer: the next generation.
Douglas Hanahan, Robert A Weinberg. Cell 2011
9

Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy.
Suzanne L Topalian, Janis M Taube, Robert A Anders, Drew M Pardoll. Nat Rev Cancer 2016
8

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
Julie Brahmer, Karen L Reckamp, Paul Baas, Lucio Crinò, Wilfried E E Eberhardt, Elena Poddubskaya, Scott Antonia, Adam Pluzanski, Everett E Vokes, Esther Holgado,[...]. N Engl J Med 2015
8

Pembrolizumab for the treatment of non-small-cell lung cancer.
Edward B Garon, Naiyer A Rizvi, Rina Hui, Natasha Leighl, Ani S Balmanoukian, Joseph Paul Eder, Amita Patnaik, Charu Aggarwal, Matthew Gubens, Leora Horn,[...]. N Engl J Med 2015
8

Delivery technologies for cancer immunotherapy.
Rachel S Riley, Carl H June, Robert Langer, Michael J Mitchell. Nat Rev Drug Discov 2019
446
8

Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.
Padmanee Sharma, Siwen Hu-Lieskovan, Jennifer A Wargo, Antoni Ribas. Cell 2017
8

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.
Julie R Brahmer, Christina Lacchetti, Bryan J Schneider, Michael B Atkins, Kelly J Brassil, Jeffrey M Caterino, Ian Chau, Marc S Ernstoff, Jennifer M Gardner, Pamela Ginex,[...]. J Clin Oncol 2018
8

Pembrolizumab versus Ipilimumab in Advanced Melanoma.
Caroline Robert, Jacob Schachter, Georgina V Long, Ana Arance, Jean Jacques Grob, Laurent Mortier, Adil Daud, Matteo S Carlino, Catriona McNeil, Michal Lotem,[...]. N Engl J Med 2015
7

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.
Matthew D Hellmann, Tudor-Eliade Ciuleanu, Adam Pluzanski, Jong Seok Lee, Gregory A Otterson, Clarisse Audigier-Valette, Elisa Minenza, Helena Linardou, Sjaak Burgers, Pamela Salman,[...]. N Engl J Med 2018
7

Oncology meets immunology: the cancer-immunity cycle.
Daniel S Chen, Ira Mellman. Immunity 2013
7


Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade.
Spencer C Wei, Jacob H Levine, Alexandria P Cogdill, Yang Zhao, Nana-Ama A S Anang, Miles C Andrews, Padmanee Sharma, Jing Wang, Jennifer A Wargo, Dana Pe'er,[...]. Cell 2017
541
7

CAR T cell immunotherapy for human cancer.
Carl H June, Roddy S O'Connor, Omkar U Kawalekar, Saba Ghassemi, Michael C Milone. Science 2018
872
6

Nivolumab in previously untreated melanoma without BRAF mutation.
Caroline Robert, Georgina V Long, Benjamin Brady, Caroline Dutriaux, Michele Maio, Laurent Mortier, Jessica C Hassel, Piotr Rutkowski, Catriona McNeil, Ewa Kalinka-Warzocha,[...]. N Engl J Med 2015
6

The future of immune checkpoint therapy.
Padmanee Sharma, James P Allison. Science 2015
6

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
Suzanne L Topalian, F Stephen Hodi, Julie R Brahmer, Scott N Gettinger, David C Smith, David F McDermott, John D Powderly, Richard D Carvajal, Jeffrey A Sosman, Michael B Atkins,[...]. N Engl J Med 2012
6

Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
Leena Gandhi, Delvys Rodríguez-Abreu, Shirish Gadgeel, Emilio Esteban, Enriqueta Felip, Flávia De Angelis, Manuel Domine, Philip Clingan, Maximilian J Hochmair, Steven F Powell,[...]. N Engl J Med 2018
6

Understanding the tumor immune microenvironment (TIME) for effective therapy.
Mikhail Binnewies, Edward W Roberts, Kelly Kersten, Vincent Chan, Douglas F Fearon, Miriam Merad, Lisa M Coussens, Dmitry I Gabrilovich, Suzanne Ostrand-Rosenberg, Catherine C Hedrick,[...]. Nat Med 2018
6

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.
Roy S Herbst, Paul Baas, Dong-Wan Kim, Enriqueta Felip, José L Pérez-Gracia, Ji-Youn Han, Julian Molina, Joo-Hang Kim, Catherine Dubos Arvis, Myung-Ju Ahn,[...]. Lancet 2016
6

Molecular and cellular insights into T cell exhaustion.
E John Wherry, Makoto Kurachi. Nat Rev Immunol 2015
6

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.
Naiyer A Rizvi, Matthew D Hellmann, Alexandra Snyder, Pia Kvistborg, Vladimir Makarov, Jonathan J Havel, William Lee, Jianda Yuan, Phillip Wong, Teresa S Ho,[...]. Science 2015
6

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.
Dung T Le, Jennifer N Uram, Hao Wang, Bjarne R Bartlett, Holly Kemberling, Aleksandra D Eyring, Andrew D Skora, Brandon S Luber, Nilofer S Azad, Dan Laheru,[...]. N Engl J Med 2015
6

Immune Checkpoint Blockade in Cancer Therapy.
Michael A Postow, Margaret K Callahan, Jedd D Wolchok. J Clin Oncol 2015
6


Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.
Daniel Y Wang, Joe-Elie Salem, Justine V Cohen, Sunandana Chandra, Christian Menzer, Fei Ye, Shilin Zhao, Satya Das, Kathryn E Beckermann, Lisa Ha,[...]. JAMA Oncol 2018
648
6

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.
Dung T Le, Jennifer N Durham, Kellie N Smith, Hao Wang, Bjarne R Bartlett, Laveet K Aulakh, Steve Lu, Holly Kemberling, Cara Wilt, Brandon S Luber,[...]. Science 2017
5



Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer.
Ugur Sahin, Evelyna Derhovanessian, Matthias Miller, Björn-Philipp Kloke, Petra Simon, Martin Löwer, Valesca Bukur, Arbel D Tadmor, Ulrich Luxemburger, Barbara Schrörs,[...]. Nature 2017
927
5

Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial.
Padmanee Sharma, Margitta Retz, Arlene Siefker-Radtke, Ari Baron, Andrea Necchi, Jens Bedke, Elizabeth R Plimack, Daniel Vaena, Marc-Oliver Grimm, Sergio Bracarda,[...]. Lancet Oncol 2017
799
5

Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors.
Angeliki M Stamatouli, Zoe Quandt, Ana Luisa Perdigoto, Pamela L Clark, Harriet Kluger, Sarah A Weiss, Scott Gettinger, Mario Sznol, Arabella Young, Robert Rushakoff,[...]. Diabetes 2018
174
5

CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer.
Laura M McLane, Mohamed S Abdel-Hakeem, E John Wherry. Annu Rev Immunol 2019
385
5

B cells and tertiary lymphoid structures promote immunotherapy response.
Beth A Helmink, Sangeetha M Reddy, Jianjun Gao, Shaojun Zhang, Rafet Basar, Rohit Thakur, Keren Yizhak, Moshe Sade-Feldman, Jorge Blando, Guangchun Han,[...]. Nature 2020
430
5

Regulation and Function of the PD-L1 Checkpoint.
Chong Sun, Riccardo Mezzadra, Ton N Schumacher. Immunity 2018
536
5

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.
Tony S K Mok, Yi-Long Wu, Iveta Kudaba, Dariusz M Kowalski, Byoung Chul Cho, Hande Z Turna, Gilberto Castro, Vichien Srimuninnimit, Konstantin K Laktionov, Igor Bondarenko,[...]. Lancet 2019
973
5

TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.
Sanjeev Mariathasan, Shannon J Turley, Dorothee Nickles, Alessandra Castiglioni, Kobe Yuen, Yulei Wang, Edward E Kadel, Hartmut Koeppen, Jillian L Astarita, Rafael Cubas,[...]. Nature 2018
5

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.
Achim Rittmeyer, Fabrice Barlesi, Daniel Waterkamp, Keunchil Park, Fortunato Ciardiello, Joachim von Pawel, Shirish M Gadgeel, Toyoaki Hida, Dariusz M Kowalski, Manuel Cobo Dols,[...]. Lancet 2017
5

Genetic basis for clinical response to CTLA-4 blockade in melanoma.
Alexandra Snyder, Vladimir Makarov, Taha Merghoub, Jianda Yuan, Jesse M Zaretsky, Alexis Desrichard, Logan A Walsh, Michael A Postow, Phillip Wong, Teresa S Ho,[...]. N Engl J Med 2014
5

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.
Jonathan E Rosenberg, Jean Hoffman-Censits, Tom Powles, Michiel S van der Heijden, Arjun V Balar, Andrea Necchi, Nancy Dawson, Peter H O'Donnell, Ani Balmanoukian, Yohann Loriot,[...]. Lancet 2016
5

Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors.
Jonathan M Pitt, Marie Vétizou, Romain Daillère, María Paula Roberti, Takahiro Yamazaki, Bertrand Routy, Patricia Lepage, Ivo Gomperts Boneca, Mathias Chamaillard, Guido Kroemer,[...]. Immunity 2016
447
5

T cell exhaustion.
E John Wherry. Nat Immunol 2011
5


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.